| Breast cancer is one of the women's major malignant tumors. In recent years, the incidence of breast cancer increases
rapidly in our country. Some studies showed that neoadjuvant chemotherapy could convert an inoperable to a surgical resectable cancer
and increase the rate of breast conserving therapy, but about 20% of the patients couldn't benefit from the neoadjuvant chemotherapy,
which further affected the subsequent treatment. Therefore, it was particularly important to develop reasonable and individualized neoadjuvant
chemotherapy for improving the quality of the survival of patients with breast cancer as well as their prognosis. Until now, the
main researches included tumor types, molecular classification, ER, PR, Ki67, etc. However, HER2, TOP2A, P53, PRAP alone as predictors
still remained controversial. In this article, an overview of predicting the efficacy, the status quo of neoadjuvant chemotherapy and its
deficiency for breast cancer were reviewed. |
